Fairscale Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Fairscale Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.2K	Buy	385 +138	+56%	+$17.2K	0.03%	198
2025 Q4	$30.1K	Hold	247	–	–	0.02%	229
2025 Q3	$24.7K	Hold	247	–	–	0.02%	256
2025 Q2	$21.2K	Buy	247 +236	+2,145%	+$18.8K	0.02%	264
2025 Q1	$892	Hold	11	–	–	﹤0.01%	327
2024 Q4	$991	Hold	11	–	–	﹤0.01%	330
2024 Q3	$1.09K	Hold	11	–	–	﹤0.01%	323
2024 Q2	$1.12K	Buy	+11	New	+$986	﹤0.01%	329

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fairscale Capital's XBI Position: Q1 2026 in Review

Fairscale Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 56% in Q1 2026, buying an estimated $17.2K and bringing the position to 385 shares worth $49.2K. The position accounts for 0.03% of the portfolio, ranked #198.

Fairscale Capital first reported a position in XBI in Q2 2024 and has held it in 8 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Fairscale Capital held 385 shares of State Street SPDR S&P Biotech ETF worth $49.2K as of Q1 2026.
Fairscale Capital bought 138 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $17.2K.
State Street SPDR S&P Biotech ETF made up 0.03% of Fairscale Capital's portfolio in Q1 2026, its #198 holding.
Fairscale Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and has held it in 8 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.